TrialAmerican journal of hematology2024

A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia.

Wei-Ying Jen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.